Study shows Flublok Quadrivalent vaccine effective against influenza- Protein Sciences Corp

Protein Sciences Corporation announced topline data showing that Flublok Quadrivalent � the quadrivalent version of FDA-approved trivalent Flublok influenza vaccine � outperformed a traditional influenza vaccine last season and was better at preventing the flu. The company presented the results of a clinical trial comparing Flublok Quadrivalent to a traditional egg-based quadrivalent inactivated vaccine. The data demonstrate superior performance of Flublok based on a significantly lower number of people contracting the flu after vaccination with Flublok Quadrivalent. In this study of approximately 9,000 subjects aged 50 and older, half received Flublok Quadrivalent influenza vaccine and half received quadrivalent inactivated influenza vaccine produced in eggs. The results show that 31% more people were protected by Flublok than by the egg-derived vaccine.

Trivalent Flublok is approved for people 18 and older to prevent influenza disease. Flublok is the only flu vaccine made without the use of eggs and therefore is not subject to the mutations that are sometimes introduced into the vaccine during the process of egg adaptation that can cause the traditional vaccines to be ineffective.